Meet Van Morris, M.D.
Van Karlyle Morris, M.D.
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2016 | University of Texas Health Science Center, Houston, TX, USA, MS, Biomedical Sciences |
| 2008 | University of Tennessee Health Sciences Center, Memphis, TN, USA, MD, Doctor of Medicine |
| 2002 | University of North Carolina, Chapel Hill, NC, USA, BS, Chemistry |
Postgraduate Training
| 2014-2015 | Research Instructor, Department of Gastrointestinal Medical Oncology, University of Texas - MD Anderson Cancer Center, Houston, TX |
| 2011-2014 | Clinical Fellowship, Hematology / Oncology, Division of Cancer Medicine, University of Texas - MD Anderson Cancer Center, Houston, TX |
| 2009-2011 | Clinical Residency, Internal Medicine, Duke University, Durham, NC |
| 2008-2009 | Clinical Internship, Internal Medicine, Duke University, Durham, NC |
Experience & Service
Institutional Committee Activities
Executive Committee Member, NCTN LAPS Committee, 2021 - Present
Chair, Translational Molecular Pathology - Clinical Research Group, 2021 - Present
Member, Pharmacy and Therapeutics Committee, 2019 - Present
Chair, Colorectal Cancer Multidisciplinary Conference, 2019 - Present
Honors & Awards
| 2015 | Khalifa Scholar Award, MD Anderson Cancer Center |
| 2014 | Achievement in Clinical Investigation, MD Anderson Cancer Center |
| 2013 | ASCO Conquer Cancer Foundation Merit Award, American Society of Clinical Oncology |
| 2013 | Young Investigator Award, American Society of Clinical Oncology |
| 2010 | Barton Haynes Housestaff Research Award, Duke Department of Medicine |
| 2008 | Alpha Omega Alpha, University of Tennessee College of Medicine |
| 2008 | Robert L. Summit, M.D. Distinguished Student Achievement Award, University of Tennessee College of Medicine |
| 2008 | University of Tennessee Health Science Center Distinguished Student Service Award, University of Tennessee College of Medicine |
| 2002 | American Institute of Chemists Graduation Award, University of North Carolina |
| 2002 | Graduate with Highest Honors, University of North Carolina Department of Chemistry |
| 2001 | Phi Beta Kappa, University of North Carolina |
Professional Memberships
Society for Immunotherapy of Cancer
Member, Gastrointestinal Cancers Immunotherapy Guideline Expert Panel, 2021 - Present
NSABP Colorectal Cancer Think Tank
Member, 2021 - Present
ASCO
Chair, Metastatic Colorectal Cancer Guideline Committee, 2021 - Present
NCI Colon Cancer Task Force
Member, 2018 - Present
Southwest Oncology Group
Member, Gastrointestinal Cancer Committee, 2018 - Present
NRG Oncology Group
Member, Gastrointestinal Cancer Committee, 2016 - Present
Selected Publications
Peer-Reviewed Articles
- Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 21(1):e28-e37, 2022. e-Pub 2021. PMID: 34794903.
- De B, Ludmir EB, Messick CA, Cagley MC, Morris VK, Das P, Minsky BD, Taniguchi CM, Smith GL, Koay EJ, Koong AC, Mohan R, Holliday EB. Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. J Gastrointest Oncol 12(5):2412-2422, 2021. PMID: 34790402.
- Verbus EA, Rossi AJ, Luna AJ, Iqbal A, Morris VK, Hernandez JM. Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy for Patients with Stage 2A Colon Cancer (COBRA). Ann Surg Oncol 28(8):4095-4097, 2021. e-Pub 2021. PMID: 33999346.
- Antonoff MB, Morris VK. Reply: Biology is king, but metastasectomy still has a role for properly selected patients. J Thorac Cardiovasc Surg 162(1):e136-e138, 2021. e-Pub 2021. PMID: 33419552.
- Hester R, Advani S, Rashid A, Holliday E, Messick C, Das P, You YN, Taniguchi C, Koay EJ, Bednarski B, Rodriguez-Bigas M, Skibber J, Wolff R, Chang GJ, Minsky BD, Foo WC, Rothschild N, Morris VK, Eng C. CEA as a blood-based biomarker in anal cancer. Oncotarget 12(11):1037-1045, 2021. e-Pub 2021. PMID: 34084278.
- Ludford K, Cohen R, Svrcek M, Foo WC, Colle R, Parc Y, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Andre T. Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer. J Natl Cancer Inst 113(2):208-211, 2021. e-Pub 2020. PMID: 32294214.
- Kopetz S, Guthrie KA, Morris VK, Lenz HJ, Magliocco AM, Maru D, Yan Y, Lanman R, Manyam G, Hong DS, Sorokin A, Atreya CE, Diaz LA, Allegra C, Raghav KP, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol 39(4):285-294, 2021. e-Pub 2020. PMID: 33356422.
- Morris VK, Strickler JH. Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer. Annu Rev Med 72:399-413, 2021. PMID: 33502901.
- Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34250391.
- Dasari A, Morris VK , Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17(12):757-770, 2020. e-Pub 2020. PMID: 32632268.
- Morris VK, Bekaii-Saab T. Improvements in Clinical Outcomes for BRAFV600E-mutant Metastatic Colorectal Cancer. Clin Cancer Res 26(17):4435-4441, 2020. e-Pub 2020. PMID: 32253230.
- Clifton K, Rich TA, Parseghian C, Raymond VM, Dasari A, Pereira AA, Willis J, Loree JM, Bauer TM, Chae YK, Sherrill G, Fanta P, Grothey A, Hendifar A, Henry D, Mahadevan D, Nezami M, Tan B, Wainberg ZA, Lanman R, Kopetz S, Morris VK.. Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay. JCO Precision Oncology, 2019. e-Pub 2019.
- Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris VK , Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. e-Pub 2019. PMID: 31566309.
- Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK , Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer 125(12):2002-2010, 2019. e-Pub 2019. PMID: 30854646.
- Lee HM, Morris V, Napolitano S, Kopetz S. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer. Oncology (Williston Park) 33(6):206-11, 2019. PMID: 31219603.
- Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-challenge. Ann Oncol. e-Pub 2018. PMID: 30462160.
- Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK , Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2017. PMID: 29180604.
- Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(4):446-453, 2017. e-Pub 2017. PMID: 28223062.
- Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov 6(12):1352-1365, 2016. e-Pub 2016. PMID: 27729313.
- Overman MJ, Morris,VK , Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. e-Pub 2016. PMID: 27542211.
- Overman MJ, Morris,VK, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
- Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris VK, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 33(34):4032-8, 2015. e-Pub 2015. PMID: 26460303.
- Pereira AA, Rego JF, Morris VK, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer 112(3):424-8, 2015. e-Pub 2014. PMID: 25535726.
- Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 25(10):2008-14, 2014. e-Pub 2014. PMID: 25009008.
- Morris VK, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
- Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14:660, 2014. e-Pub 2014. PMID: 25208577.
- Morris VK, Kopetz S. Clinical biomarkers in colorectal cancer. Clin Adv Hematol Oncol 11(12):768-76, 2013. PMID: 24893280.
- Morris VK, Kopetz S. BRAF inhibitors in clinical oncology. F1000Prime Rep 5:11, 2013. e-Pub 2013. PMID: 23585929.
Invited Articles
- Morris V, Dasari A, Kopetz S. Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncol. e-Pub 2019. PMID: 31070713.
- Morris VK, Eng C. Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. J Natl Compr Canc Netw 16(7):903-908, 2018. PMID: 30006430.
Editorials
- Morris VK. Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral. Clin Cancer Res 25(7):2030-2032, 2019. PMID: 30655314.
Abstracts
- Morelli MP, Overman MJ, Dasari A, Kazmi SM, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
Book Chapters
- Morris VK. Colorectal Cancer. In: The MD Anderson Manual of Medical Oncology 3rd edition, 2016.
- Morris VK. Anal Cancer. In: The MD Anderson Manual of Medical Oncology 3rd edition, 2016.
Grant & Contract Support
| Date: | 2024 - 2029 |
| Title: | Optimizing TIL therapy and understanding tumor immune microenvironment in colorectal carcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | FP21758 PA-20-183 |
| Date: | 2023 - 2030 |
| Title: | A Phase 1/1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1454 |
| Funding Source: | Sumitomo Dainippon Pharma Oncology, Inc |
| Role: | Principal Investigator |
| ID: | 2023-0481 | TP-1454-101 | PID15529 |
| Date: | 2022 - 2024 |
| Title: | Targeting adaptive mutability as a novel therapeutic approach for pMMR,BRAFV600E metastatic colorectal cancer |
| Funding Source: | The Andrew Sabin Family Foundation Fellowship Award FY22 – UT MD Anderson Cancer Center |
| Role: | Principal Investigator |
| ID: | NA |
| Date: | 2022 - 2029 |
| Title: | Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant, MSIH/ dMMR Metastatic Colorectal Cancer |
| Funding Source: | Pfizer Inc |
| Role: | Principal Investigator |
| ID: | 2022-0254 | PID14000 |
| Date: | 2022 - 2025 |
| Title: | Therapeutic approaches for TGF-beta-enriched minimal residual disease in patients with colorectal cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Principal Investigator |
| ID: | FP13942 |
| Date: | 2022 - 2023 |
| Title: | Targeting adaptive mutability as a novel therapeutic approach in BRAF mutant colorectal cancer |
| Funding Source: | Institutional Research Grant (IRG) – UT MD Anderson Cancer Center |
| Role: | Principal Investigator |
| ID: | NA |
| Date: | 2021 - 2026 |
| Title: | An Open-Label, Multi-Center, Phase II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations with Standard of Care (SOC) Anti-Cancer Therapy for the Second Line Treatment of Meta |
| Funding Source: | Novartis |
| Role: | Principal Investigator |
| ID: | 2021-0910 | PID13428 |
| Date: | 2021 - 2024 |
| Title: | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients |
| Funding Source: | ECOG-ACRIN Research Cancer Group |
| Role: | Principal Investigator |
| ID: | 2020-1247 (EA21761) |
| Date: | 2021 - 2025 |
| Title: | Phase II/III study of ctDNA as a predictive biomarker in adjuvant chemotherapy in patients with stage IIA colon cancer (NRG GI-005) |
| Funding Source: | NRG |
| Role: | Principal Investigator |
| ID: | 2020-0107 | NRG-G1005| PID13192 |
| Date: | 2021 - 2028 |
| Title: | A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection |
| Funding Source: | BioNTech RNA Pharmaceuticals GmbH |
| Role: | Principal Investigator |
| ID: | 2020-1060 | PID12293 |
| Date: | 2020 - 2027 |
| Title: | An open-label, multicenter, randomized phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic braf v600e-mutant colorectal cancer |
| Funding Source: | Pfizer |
| Role: | Principal Investigator |
| ID: | 2020-0879/PID11983 |
| Date: | 2020 - 2027 |
| Title: | First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Alone and in Combination with Pembrolizumab in Patients with EGFR-Driven Advanced Solid Tumors |
| Funding Source: | Bicara Therapeutics, Inc |
| Role: | Principal Investigator |
| ID: | 2020-0153/PID13261 |
| Date: | 2019 - 2026 |
| Title: | Phase I/II Trial of Encorafenib, Cetuximab, and Nivolumab in Microsatellite Stable BRAFV600E Metastatic Colorectal Cancer |
| Funding Source: | Array |
| Role: | Principal Investigator |
| ID: | 2018-0993 | PID7721 |
| Date: | 2019 - 2025 |
| Title: | UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1 |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | 5UG1CA233329 Admin Core |
Patient Reviews
4.9/5
Listened Carefully to You
5/5
Explanations Easy to Understand
4.9/5
Knew Your Medical History
4.9/5
Gave Easy to Understand Instructions
4.9/5
Spent Enough Time With You
5/5
Showed Respect for You
5/5
Would Recommend Provider’s Office
4.8/5
Provider Rating 0 - 10
Comments (51)
Caring doctor
Very knowledgeable in his medical specialty , caring , and well spoken....
I've been Dr. Morris' patient for more than 8 years. He's always been very professional and caring. When he walks into the examining room, he is always updated on all of my recent CT scans. He explains everything to me and makes sure I understand. He proceeds to explain my...
Dr Morris and his team were authentic, reviewed MRI results that were ordered as result of something found during an ER visit, helped answer questions and made the atmosphere light and welcoming.
I couldn't ask for a better team of doctors for my care. Dr. Morris and Dr. You were professional and conscientious to seek the best treatment for my case and their team took great care to address any issues that came up and to ensure that I was able to function at my best...
Very professional and knowledgeable
Dr. Morris is the best doctor I have ever seen in my life. I am blessed to have him during my fight with stage 4 cancer
Dr Morris has always listened to me about my concerns and seems to truly care about me.
Dr. Morris was informed, patient with us, knowledgeable, and really listened to the questions and concerns that we had. We would highly recommend him.
Excellent care provided by provider.
He and his team are the best in the world!
He explained the clinical trial to me clearly and concisely. I understood the background and reason for the trial. He answered my questions and addressed my concerns.
Excellent information
Dr. Van Morris is the most outstanding physician at MD Anderson, the Number One Cancer Center in the United States! He provides nationally recognized amazing leading edge cancer treatment. Jocelyn Mitchell is an amazing kind, caring, compassionate Physician Assistant! Thank...
Dr. Morris is absolutely amazing!! He's brilliant.
I thought the provider is very good. The issue that I have with MD Anderson is how the communication and the feedback is affected on scheduling. Since you have multiple locations around the city, there are some convenient places that patients can go to, but there is a lack...
Only the best experience
Dr. Van Morris has been my provider for the last eight years and he has been awesome. He is very caring and attentive and professional. He always makes me feel like I am his only patient and he answers any questions or concerns I have and he never dismisses any of my...
Expresses genuine interest and concern regarding my illness.
Excellent
Dr Morris and team are amazing and I am very thankful for them!
For Dr. Morris and for Dr. Banarski, extremely excellent physician, professional in their own right. My only advice is never to change. Excellent bedside manners, very well in explaining it to where the patient understands and answers all loved ones' questions. Thank you...
He came in and explained everything about the test we had and gave me great news. And answered all the questions that we had.
My visit with Dr. Morris was great. He answered all my questions and most importantly, the way he delivered my results, him and his colleagues, which I can't remember his name right now, they were both very professional, awesome and very caring. And I would definitely...
Dr. Morris and staff are the best!
The experience has been beyond my expectations, by far. Dr. Morris answers all my questions with patience. He is obviously completely up to date in the field of care for patients with my diagnosis. He is encouraging and kind. All staff have been wonderful
I had a wonderful experience.
Dr Morris is a fabulous Dr and he always explains things to me where I can understand them.
Professional, friendly service. Took care of all of my problems. Would definitely recommend this practice to anyone.
Dr. Morris is an absolutely doctor. He was able to quickly identify the solution to a problem that stumped my oncologists and prevented me from getting treatment for my Stage 4 cancer in my home State for 4 months. He truly gave me the miracle I needed to get back into...
Dr. Morrison and his office staff are awesome.
Very good experience with Dr. Morris and his team.
Dr. Van Morris is the most outstanding oncologist at MD Anderson, the number one Cancer Center in the US.He is amazing, kind, compassionate, caring and fellowship trained in the most advanced cancer treatments. Thank you Dr. Morris for curing my rectal cancer!
Dr. Van Morris is the most outstanding, kind compassionate oncologist at MD Anderson! Thank you Dr. Morris for curing my rectal cancer! Jocelyn Mitchell is an amazing, awesome PA!
My experience at MD Anderson last week was phenomenal. Everybody that I interacted with were so kind and caring and compassionate. Dr. Morris was amazing. I liked how he figured out how to talk in easy to understand words to explain to me what was going on. I really...
My doctor, Van Karlyle Morris, is attentive and reassuring, period. He does not give us false hope, but also doesn't allow us to pay attention to only the negative statistics, period. He's a wonderful person to talk to and an excellent doctor. We are thrilled with him.
Mr. Morris took time and explained things to us, whereas back home the oncologist didn't do.
He is very informative and good bedside manner. And he's so good with information. And he supplied everything, information and knowledge about my concerns. Thank you.
Dr. Morris showed great concern over my liver failure and he took appropriate action. Then he even called personally to follow up. Very impressed with this service.
Outstanding
The whole MD Anderson experience has been remarkable to say the least. Dr. Morris and his team have been so very responsive under very difficult circumstances to say the least. Thank them all.
All of MD Anderson's are very supportive, loving, and helpful. I highly recommend this hospital to anyone in the world. We are very grateful that we are a part of MD Anderson's team.
Dr. Morris is an excellent oncologist that cares about his patients and their quality of life. I felt like he treated me as he would have treated his mother. His assistants are also very caring and kind.
I have been seeing Dr. Van Morris for 7 years during my battle with cancer. He has always been the most caring and respectful doctor. I feel extremely comfortable with him and trust that he always has his best interest in my medical care. My family and I trust him...
Great
Excellent experience. He is knowledgeable, thoughtful and kind. He took the time to really listen to every question and the time to understand the whole picture not just what was in front of him.
I absolutely love Dr. Morris, his PAs and his nurses. They always answer my questions and have the utmost compassion when I am afraid. Couldn't ask for more.
I think Dr Morris was professional & kind. He answered all my questions & listened to me & my concerns!
Dr. Van Morris is committed beyond what any doctor I have ever had to treating his patients, period. He is, without question, the world's leading expert in my rare cancer and uses all of his knowledge and experience to provide me with the best care plan I could possibly...
I really enjoyed seeing Dr. Morris. I thought he was a wonderful doctor. He spent plenty of time with me. He was very knowledgeable about what's going on. Fortunately, he had good news to give me, but I would go back to see him in a heartbeat if I needed to. I would...
CV information above last modified September 04, 2024
Request an Appointment
Whether you are ready to make an appointment now or have questions for our expert team, we are standing by to help.
Clinical Trials
Our patients have access to clinical trials offering promising new treatments that cannot be found anywhere else.